ArticleJournal of the Chinese Medical Association : JCMA2026
An in-hospital referral program for hepatitis C virus elimination in patients with type 2 diabetes mellitus.
Article in Journal of the Chinese Medical Association : JCMA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe World Health Organization's goal of hepatitis C virus (HCV) elimination by 2030 remains a challenge. While type 2 diabetes mellitus (T2DM) is associated with HCV infection, identifying unrecognized cases in low-endemic areas is difficult. This study evaluates the feasibility and outcomes of a hospital-based microelimination referral program in T2DM patients and explores chronic kidney disease (CKD) stage as a potential risk stratifier.
methodsIn this prospective study (March 2022-May 2023), T2DM patients enrolled in a pay-for-performance program underwent routine anti-HCV antibody screening. Seropositive patients were referred to hepatologists for HCV-RNA testing and direct-acting antiviral (DAA) evaluation. We used multivariable logistic regression to identify baseline predictors of HCV viremia and piecewise generalized estimating equations (GEE) to assess the impact of viremia and DAA therapy on estimated glomerular filtration rate (eGFR) trajectories.
resultsAmong 4402 T2DM patients, 104 (2.4%) were anti-HCV positive. Seroprevalence increased across CKD stages 1 to 5 (1.8%, 2.3%, 2.6%, 3.5%, and 7.8%; p = 0.014). Furthermore, among anti-HCV-positive patients, the proportion of advanced CKD (stages 3-5) significantly increased in those with higher Fibrosis-4 (FIB-4) index scores ( p = 0.020). Multivariable analysis of HCV viremia identified lower diastolic blood pressure (odds ratio [OR], 0.968; p = 0.017), total cholesterol (OR, 1.012; p = 0.015), triglycerides (OR, 0.991; p = 0.008), and alanine aminotransferase (OR, 1.011; p = 0.006) as independent predictors. While untreated viremia initially appeared to accelerate eGFR decline, this effect was attenuated after adjusting for age and glycated hemoglobin (HbA1c). Moreover, eGFR decline trajectories did not change significantly following DAA therapy.
conclusionAn in-hospital referral program for T2DM patients is feasible for HCV microelimination, using CKD staging as a practical risk stratifier. Despite DAA renal safety, diabetes-associated kidney damage may drive post-cure renal progression, necessitating continuous metabolic management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.